Shield Therapeutics Future Growth
Future criteria checks 6/6
Shield Therapeutics is forecast to grow earnings and revenue by 86.9% and 47.7% per annum respectively. EPS is expected to grow by 76.2% per annum. Return on equity is forecast to be 95% in 3 years.
Key information
86.9%
Earnings growth rate
76.2%
EPS growth rate
Pharmaceuticals earnings growth | 14.7% |
Revenue growth rate | 47.7% |
Future return on equity | 95.0% |
Analyst coverage | Low |
Last updated | 22 Feb 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 183 | N/A | 31 | N/A | 1 |
12/31/2025 | 132 | 15 | 14 | 17 | 2 |
12/31/2024 | 67 | -14 | -16 | -13 | 3 |
12/31/2023 | 19 | -32 | -35 | -32 | 3 |
6/30/2023 | 7 | -49 | -30 | -28 | N/A |
3/31/2023 | 6 | -49 | -27 | -24 | N/A |
12/31/2022 | 5 | -49 | -23 | -21 | N/A |
9/30/2022 | 4 | -36 | -23 | -20 | N/A |
6/30/2022 | 4 | -30 | -31 | -27 | N/A |
3/31/2022 | 3 | -29 | -29 | -26 | N/A |
12/31/2021 | 2 | -27 | -27 | -25 | N/A |
9/30/2021 | 2 | -22 | -21 | -20 | N/A |
6/30/2021 | 3 | -18 | -16 | -16 | N/A |
3/31/2021 | 9 | -11 | -9 | -9 | N/A |
12/31/2020 | 14 | -4 | -2 | -2 | N/A |
9/30/2020 | 13 | -3 | -1 | -1 | N/A |
6/30/2020 | 11 | -2 | 0 | 0 | N/A |
3/31/2020 | 6 | -6 | -4 | -3 | N/A |
12/31/2019 | 1 | -12 | -7 | -5 | N/A |
9/30/2019 | 8 | -4 | -1 | 1 | N/A |
6/30/2019 | 15 | 3 | 4 | 6 | N/A |
3/31/2019 | 15 | 0 | 0 | 3 | N/A |
12/31/2018 | 15 | -2 | -4 | 0 | N/A |
9/30/2018 | 8 | -13 | -14 | -9 | N/A |
6/30/2018 | 1 | -24 | -24 | -19 | N/A |
3/31/2018 | 1 | -26 | -26 | -21 | N/A |
12/31/2017 | 1 | -26 | -26 | -22 | N/A |
9/30/2017 | 1 | -24 | -25 | -21 | N/A |
6/30/2017 | 0 | -21 | -24 | -19 | N/A |
3/31/2017 | 0 | -19 | N/A | -16 | N/A |
12/31/2016 | 0 | -19 | N/A | -13 | N/A |
9/30/2016 | 0 | -12 | N/A | -12 | N/A |
6/30/2016 | 0 | -4 | N/A | -10 | N/A |
3/31/2016 | 0 | -19 | N/A | -8 | N/A |
12/31/2015 | N/A | -35 | N/A | -6 | N/A |
9/30/2015 | 0 | -41 | N/A | -5 | N/A |
6/30/2015 | 0 | -49 | N/A | -4 | N/A |
3/31/2015 | 0 | -33 | N/A | -5 | N/A |
12/31/2014 | 0 | -20 | N/A | -5 | N/A |
12/31/2013 | 0 | -7 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: STX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: STX is expected to become profitable in the next 3 years.
Revenue vs Market: STX's revenue (47.7% per year) is forecast to grow faster than the UK market (3.3% per year).
High Growth Revenue: STX's revenue (47.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STX's Return on Equity is forecast to be very high in 3 years time (95%).